Dermatology
Downregulation of Fas ligand might improve skin disorder pathogenesis
Published in Cancer Weekly, August 5th, 2003
According to recent research published in the Journal of Investigative Dermatology, "Fas ligand (FasL), a member of the tumor necrosis factor family, induces apoptosis upon interaction with Fas-receptor-expressing cells. FasL normally plays an important immune regulatory role, but it can also cause severe skin diseases if overexpressed and it may serve some tumors for immune evasion. Thus, in situ inhibition of FasL expression with antisense oligonucleotides in patients may be a novel approach to overcome its pathogenic role."
"We designed and evaluated 15 phosphorothioate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-08-05)
More Articles from Cancer Weekly
- Oncogenes
Researchers identify secondary pathway for survival of cancer cells - RNA Interference
Scientists test new method to attack cancer - Cancer Therapy
Scientists find antitumor compounds in magnolia cones - Leukemia
Sequential chemotherapy is effective for newly diagnosed de novo AML - Oncology
Tumor-associated gangliosides modulate biological behaviors in tumors - Squamous Cancer
PD-ECGF causes head and neck cancers to cycle through growth phases quickly - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
